SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report second quarter 2015 financial results on August 4, 2015. Ligand’s CEO John Higgins, President and COO Matt Foehr and interim CFO Melanie Herman will host the conference call.
|Second Quarter Earnings Call|
|What:||Ligand conference call to discuss financial results and provide general business updates|
|When:||Tuesday, August 4, 2015|
|Time:||1:30 p.m. Pacific time (4:30 p.m. Eastern time)|
Conference call and replay accessible at www.ligand.com
|Conference Call:||(877) 407-4019 within the U.S.|
|(201) 689-8337 outside the U.S.|
|Replay:||(877) 660-6853 within the U.S.|
|(201) 612-7415 outside the U.S.|
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company with a business model focused on developing or acquiring royalty generating assets and coupling them with a lean corporate cost structure. Ligand’s goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer’s disease, dyslipidemia, anemia, asthma and osteoporosis. Ligand’s Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Baxter International and Eli Lilly.
Follow Ligand on Twitter @Ligand_LGND.